[1] 刘朝晖,廖秦平.外阴阴道假丝酵母菌病(VVC)诊治规范修订稿[J].中华实用妇科与产科杂志,2012,28(6):401-402.
[2] NADEEM S G,HAKIM S T,KAZMI S U,et al.Use of CHROM agar Candida for the presumptive identification of Candida species directly from clinical specimens in resouse-limited settings[J].Libyan J Med,2010,5(1):2144-2149.
[3] 李春美,刘燕燕,李赛男,等.三种外阴阴道假丝酵母菌病致病菌种鉴定方法比较[J].昆明医科大学学报,2016,37(7):107-110.
[4] DAEF E,MOHARRAM A,ELDIN S S,et al.Evaluation of chromogenic-media and seminested PCR in the identification of Candida species[J].Braz J Microbiol,2014,45(1):255-262.
[5] 李红宾,黄云丽,李玉叶.rDNA-ITS序列测定等三种方法鉴定假丝酵母菌结果比较[J].中国皮肤性病学杂志,2016,30(1):91-93.
[6] 刘一婷,杜敏.阴道微生态评价体系的评价指标与临床意义[J].甘肃医药,2016,12(35):900-902.
[7] 肖冰冰,刘朝晖.阴道微生态评价在阴道炎中的应用[J].中国妇产科临床杂志,2016,6(17):483-485.
[8] 安瑞芳,张岱,刘朝晖.阴道微生态评价的临床应用专家共识[J].中华妇产科杂志,2016,51(10):721-723.
[9] SOBEL J D.Recurrent vulvovaginal candidiasis[J].Am J Obstet Gynecol,2016,214(1):15-21.
[10] 龚家红,查建梅.复发性外阴阴道假丝酵母菌病106例治疗体会[J].现代医学,2013,41(2):129-131.
[11] IAVAZZO C,GKEGKES I D,ZARKADA I M,et al.Boric acid for recurrent vulvovaginal candidiasis:the clinical evidence[J].J Womens Health (Larchmt),2011,20(8):1245-1255.
[12] 郭玉荣,赵晓丽.复发性外阴阴道假丝酵母菌病的病原菌鉴定与药敏分析[J].国际检验医学杂志,2016,37(2):251-253.
[13] 胡红珍,王丽娟,李丽萍,等.复发性外阴阴道假丝酵母菌病的菌种及药物敏感度研究[J].新医学,2016,47(9):604-608.
[14] 谭皓研,冯浩华,何艳屏.阴道白假丝酵母菌的耐药性与ABC转运蛋白基因表达的关系研究[J].现代医学,2015,43(4):409-412.
[15] 罗兰兰,李卫.口服氟康唑联合阴道用药治疗复发性外阴阴道假丝酵母菌病的疗效[J].江苏医药,2017,43(15):1106-1107.
[16] 贝筱勤.乳杆菌活菌胶囊治疗产后阴道炎100例[J].中国药业,2013,22(9):81-82.
[17] 张谦.阴道用乳杆菌活菌胶囊临床应用的价值[D].大连:大连医科大学,2014.
[18] 赵红果.调节阴道微环境在复发性阴道炎治疗中的作用分析[J].中外女性健康研究,2016(14):18-19.
[19] 李红,黄小清.乳酸杆菌活菌胶囊治疗复发性外阴阴道白假丝酵母菌病的疗效及对阴道局部免疫功能的影响[J].现代医院,2017,45(1):109-111.
[20] 叶珊珊,邢秀伟,黄瑞丽.乳酸杆菌活菌胶囊联合抗真菌药物治疗复发性外阴阴道白假丝酵母菌病的临床观察[J].河北联合大学学报:医学版,2016,18(3):208-210.
[21] GARVEY E P,HOEKSTRA W J,SCHOTZINGER R J.Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and-resistant Candida albicans in a murine model of vaginal candidiasis[J].Antimicrob Agents CH,2015,59(9):5567-5573.
[22] BRAND S,DEGENHARDT T,NYIRJESY P.15:To evaluate the efficacy and safety of VT-1161,a potent,highly selective inhibitor of fungal CYP51,in treating women with a documented history of recurrent vulvovaginal candidiasis (RVVC)[J].Am J Obstet Gynecol,2016,215(6):S821.
[23] NYIRJESY P,SOBEL J D,EDWARDS J E.18:NDV-3A vaccine reduces the frequency of vaginitis in patients with recurrent vulvovaginal candidiasis[J].Am J Obstet Gynecol,2016,215(6):S822. |